2020 Clinical practice guidelines for Stable coronary art

Russian Journal of Cardiology 25, 4076

DOI: 10.15829/29/1560-4071-2020-4076

Citation Report

#	Article	IF	CITATIONS
1	Parameters of volume computed tomography combined with adenosine triphosphate test in diagnosis of stable coronary artery disease. Kardiologicheskii Vestnik, 2021, 16, 53.	0.4	2
2	Preoperative management in coronary artery bypass surgery. The role of effective therapy. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2021, 14, 139.	0.3	3
3	Actual issues of lipid centers' operation in Russian Federation. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2759.	1.4	2
5	Aspects of practical application of â€~STOPP/START' criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi‑speciality hospital. Medical Alphabet, 2021, , 57-65.	0.2	2
6	Features of Risk Stratification, Diagnosis and Secondary Prevention in Patients with Multifocal Arterial Disease. Part 2: Treatment Options. Rational Pharmacotherapy in Cardiology, 2021, 17, 239-248.	0.8	0
7	Dynamics of blood pressure indicators in patients with diabetes mellitus after planned percutaneous coronary intervention., 2021, 17, 12-20.	0.1	O
8	Prevention of cardiovascular events in patients with stable coronary artery disease: myocardial revascularization or pharmacological treatment?. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0	rgBIA/Ove	rlo o k 10 Tf 50
9	Elderly patient with coronary artery disease. What are common problems that need solving?. Medical Alphabet, 2021, 1, 8-11.	0.2	2
10	Organization of lipid centers operation in the Russian Federation — new opportunities. Russian Journal of Cardiology, 2021, 26, 4489.	1.4	6
12	Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology, 2021, 17, 628-637.	0.8	0
13	Evidence born from ASCOT trial – still important after 15 years. Eurasian Heart Journal, 2021, , 46-53.	0.8	1
14	Choosing an antianginal therapy strategy in patients with stable coronary artery disease in real clinical practice: the advantages of trimetazidine. Meditsinskiy Sovet, 2021, , 25-32.	0.5	O
15	Comorbid conditions - a reason to strengthen antianginal therapy in patients with stable coronary artery disease. Medical Alphabet, 2021, , 49-52.	0.2	O
16	Self-care and quality of life in comorbid patients with chronic coronary syndromes: is there any correlation?. Åžno-Rossijskij žurnal TerapevtiÄeskoj Praktiki, 2021, 2, 40-47.	0.3	0
17	Fixed-dose combination of ivabradine and metoprolol in a patient with stable coronary artery disease: a case report. Russian Journal of Cardiology, 2021, 26, 4657.	1.4	0
19	Combination of chronic myocarditis and progressive coronary artery disease: differential diagnosis and stepwise treatment. Russian Journal of Cardiology, 2020, 25, 3915.	1.4	0
20	Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines. Rational Pharmacotherapy in Cardiology, 2021, 17, 761-770.	0.8	0
21	Lipid-lowering therapy in outpatients of different ages with coronary artery disease. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2654.	1.4	1

#	Article	IF	CITATIONS
22	Regional differences in cardiac mortality rates in Russia: the role of statistical features. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2928.	1.4	9
23	Đ¡linical and hemodynamic characteristics and coronary blood flow in patients with chronic coronary artery disease and type 2 diabetes. Russian Journal of Cardiology, 2022, 26, 4639.	1.4	3
25	Long-term outcomes of coronary artery bypass graft surgery in patients with widespread atherosclerotic lesions of the coronary and peripheral vascular basins (based on the REGATA) Tj ETQq0 0 0 rgBT	/Ovædock	101∫f 50 657
26	Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction. Atherothrombosis, 2022, 11, 18-28.	0.3	0
27	Healthy nutrition in secondary prevention after myocardial infarction. What to focus on?. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 2918.	1.4	2
28	The possibilities of using antiplatelet agents during and after COVID-19 disease. Results of the Expert Council meeting. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 20, 3152.	1.4	0
29	Features of the diagnosis and course of coronary heart disease in young people: a clinical case. Pacific Medical Journal, 2022, , 95-97.	0.3	0
30	Prevention continuum: an assessment of cardiovascular disease prevention based on the data from a survey of doctors. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 20, 3090.	1.4	3
31	Ischemic heart disease: medical certificate of cause of death analysis. Russian Journal of Cardiology, 2022, 27, 4637.	1.4	4
32	Pretest probability of coronary artery disease as a factor for optimizing invasive diagnostics in routine clinical practice. Russian Journal of Cardiology, 2022, 27, 4765.	1.4	2
35	Gastric mucosa condition in patients with coronary artery disease and high risk of gastrointestinal bleeding (register REGATTA-1). Terapevticheskii Arkhiv, 2021, 93, 1457-1462.	0.8	1
36	The possibilities of using antiplatelet agents during and after COVID-19 disease. Results of the Expert Council meeting. Russian Journal of Cardiology, 2022, 26, 4797.	1.4	1
37	Successful endovascular treatment of left main bifurcation lesion using the DK-CRUSH technique with intracoronary imaging using optical coherence tomography: A case report. Sibirskij žurnal KliniÄeskoj I èksperimentalʹnoj Mediciny, 2022, 37, 162-169.	0.4	0
38	How to optimize treatment in patients with different forms of coronary artery disease. Meditsinskiy Sovet, 2022, , 273-279.	0.5	1
39	Prediction of cerebrovascular complications of coronary artery bypass grafting in patients without significant stenosis of the carotid arteries. Russian Neurological Journal, 2022, 27, 34-42.	0.3	0
40	Unresolved issues of increasing physical activity after myocardial infarction. Russian Journal of Cardiology, 2022, 27, 4828.	1.4	0
41	Combined myocardial perfusion scintigraphy and computed tomography: diagnostic and prognostic value in coronary artery disease. Russian Journal of Cardiology, 2022, 27, 4925.	1.4	1
42	Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide. The Siberian Scientific Medical Journal, 2022, 42, 41-46.	0.3	O

#	ARTICLE	IF	CITATIONS
43	Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia. Sibirskij žurnal KliniÄeskoj I Óksperimentalʹnoj Mediciny, 2022, 37, 105-111.	0.4	2
44	Aromatic Amino Acids: Phenylalanine and Tyrosine in Patients with Hypertension and Coronary Artery Disease. Rational Pharmacotherapy in Cardiology, 2022, 18, 297-305.	0.8	0
45	Self-care as the Basis of the Mobile Application for Patients with Chronic Coronary Syndromes. Rational Pharmacotherapy in Cardiology, 2022, 18, 268-273.	0.8	0
46	Depressive disorders and quality of live in patients with acute coronary syndrome in real clinical practice. Klinicist, 2022, 16, 29-39.	0.5	1
47	The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiya, 2022, 62, 12-22.	0.7	2
48	Drug-induced intracerebral hemorrhage. Kachestvennaya Klinicheskaya Praktika, 2022, , 55-68.	0.5	0
49	Effective drug modification of risk factors in a patient with coronary artery disease: a case report. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3221.	1.4	0
50	Change in instantaneous wave-free ratio in the donor artery in multivessel coronary disease: a case report. Russian Journal of Cardiology, 2022, 27, 5090.	1.4	O
51	Consensus of European Experts on the Management of Patients with Ischemia with Non-Obstructive Coronary Arteries with Chronic Coronary Syndrome: Possibilities for Use in Outpatient Clinical Practice in Russia. Russian Archives of Internal Medicine, 2022, 12, 330-340.	0.2	0
52	The quality of received drug therapy in patients with stable coronary heart disease according to the ALIGN (TherApy in stabLe Coronary Artery disease Patients According to Clinical GuideliNes) study. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3371.	1.4	0
53	Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention. Complex Issues of Cardiovascular Diseases, 2022, 11, 40-50.	0.5	0
54	Differential diagnosis of angina pectoris in the practice of the regional vascular center: a clinical observation. Meditsinskiy Sovet, 2022, , 20-26.	0.5	0
55	Analysis of drug prescriptions of patients with atrial fibrillation in combination with chronic kidney disease for compliance with STOPP/START criteria. Medical Alphabet, 2022, , 12-18.	0.2	0
56	Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease. Kardiologiya, 2022, 62, 40-48.	0.7	2
57	Drug-induced non-traumatic intracranial hemorrhage associated with the use of anticoagulants and antiplatelet agents. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 80-88.	1.2	0
58	Pharmacological treatment of stable angina pectoris: the place of trimetazidine. Eurasian Heart Journal, 2022, , 82-89.	0.8	0
59	Implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death in clinical practice: analysis of the clinical and anamnestic characteristics of patients according to the Kuzbass registry. Complex Issues of Cardiovascular Diseases, 2023, 11, 139-150.	0.5	1
60	QUALITY OF LIFE IN PATIENTS WITH CORONARY HEART DISEASE AND BRONCHIAL ASTHMA. Ulyanovsk Medico-biological Journal, 2022, , 30-37.	0.2	0

#	Article	IF	CITATIONS
61	Type two diabetes mellitus and microvascular complications in patients with coronary artery disease: prevalence, prognosis and choice of antithrombotic therapy. Ûžno-Rossijskij žurnal TerapevtiÄeskoj Praktiki, 2022, 3, 7-24.	0.3	2
62	The resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelines. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 21, 3487.	1.4	2
63	Pathogenetic and clinical aspects of the development of acute coronary syndrome in influenza and COVID-19: vaccination issues. Complex Issues of Cardiovascular Diseases, 2023, 11, 163-172.	0.5	0
64	Risk factors for development of the post-COVID syndrome. Klinicist, 2023, 16, 19-26.	0.5	1
65	Health and social effectiveness of the expansion of medicine assistance programs for patients with coronary artery disease and comorbidities. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /0	Overkock 1	0 Tof 50 577 ⁻
66	Association of hypertriglyceridemia with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk. Russian Journal of Cardiology, 2023, 28, 5215.	1.4	0
67	Relationship between latent left ventricular contractile dysfunction and signs of immune inflammation in patients with COVID-19 pneumonia. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 (OOLragBT/(Ov e rlock 10⁻
68	State of the art mathematical methods of the coronary blood flow modelling: background and clinical value. Kardiologiya, 2023, 63, 77-84.	0.7	1
69	Diabetes mellitus and long-time outcomes of autovenous femoro-popliteal bypass. Diabetes Mellitus, 2023, 26, 182-191.	1.9	0
70	Follow-up organization for patients with dyslipidemia: the experience of the Republic of Tatarstan. Profilakticheskaya Meditsina, 2023, 26, 17.	0.6	0
71	Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients. V M Bekhterev Review of Psychiatry and Medical Psychology, 2023, 57, 105-115.	0.4	1
72	Review of 20-year results of ASCOT Legacy. Russian Journal of Cardiology, 2023, 28, 5457.	1.4	0
73	The role of molecular imaging in the comprehensive examination of HIV-patients with ischemic heart disease. Medical Visualization, 2023, 27, 41-52.	0.4	0
74	Analysis of coronary artery lesion degree and related risk factors in patients with coronary heart disease. Acta Biomedica Scientifica, 2023, 8, 93-102.	0.2	0
75	The HFA-PEFF diagnostic algorithm for diagnosing heart failure with preserved ejection fraction in hypertensive patients. Arterial Hypertension (Russian Federation), 2023, 29, 211-219.	0.4	0
76	Therapeutic effects of medical rehabilitation in patients suffered from coronary heart disease with lower limb amputation. Voprosy Kurortologii, Fizioterapii, I Lechebnoi Fizicheskoi Kultury, 2023, 100, 5.	0.5	0
77	Change in patients' smoking behavior after a myocardial infarction according to a multicenter study. Profilakticheskaya Meditsina, 2023, 26, 100.	0.6	0
78	Diseases of the gastrointestinal tract coronary heart disease: relationships and mutual influences. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2023, , 130-139.	0.4	0

#	ARTICLE	IF	Citations
79	Plasma branched-chain amino acid concentrations in individuals without cardiovascular diseases versus patients diagnosed with hypertension and coronary artery disease. Rational Pharmacotherapy in Cardiology, 2023, 19, 230-239.	0.8	0
80	The role of acetylsalicylic acid in the treatment of diseases caused by atherosclerosis. Atherothrombosis, 2023, 13, 23-34.	0.3	O
81	Metabolic Model for Laboratory Control of Anti-ischaemic Therapy Effectiveness: A Case Study of Nicorandil. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 0, , .	0.2	0
82	Surface-enhanced Raman spectroscopy for searching pharmacodynamic predictors of response to antiplatelet therapy. Sibirskij žurnal KliniÄeskoj I Ä ksperimentalʹnoj Mediciny, 0, , .	0.4	O
83	Modern possibilities of antihypertensive and lipid-lowering therapy in the treatment of comorbid patients with a very high risk of cardiovascular events. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3584.	1.4	0
84	Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiya, 2023, 63, 3-15.	0.7	0
85	The general concept of a patient-oriented approach to the use of drugs with cytoprotective activity in patients with coronary heart disease., 2023, 1, 1-14.		0
86	Position of the Russian Society of Cardiology experts on improving the cardiology education in medical schools in compliance with the educational continuity. Russian Journal of Cardiology, 2023, 28, 5553.	1.4	0
87	Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention. Fundamental and Clinical Medicine, 2023, 8, 44-52.	0.3	0
88	ĐĐĐ¸Đ¿Đ¾ĐĐ¸Đ½Đ¾-Ñ†Đ¸Ñ,Đ¾ĐĐ¸Đ½Đ¾Đ²Ñ‹Đ¹ Đ¿Ñ€Đ¾Ñ"Đ¸Đ»ÑŒ ĐªÑ€Đ¾Đ²Đ¸ у Đ¼ÑƒĐ¶Ñ‡Đ¸Đϟ	/2 Ñ Ð ÞÐ3/4	Ñ €Ð ¾Ð½Ð
89	Hyperammonemia in patients with stable angina pectoris and nonalcoholic fatty liver disease at the steatosis stage. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2023, , 57-65.	0.4	0
90	Effect of long-term nicorandil therapy on myocardial perfusion parameters according to triphosadenine stress-volume computed tomography in a patient with non-obstructive coronary artery disease: a care report. Rational Pharmacotherapy in Cardiology, 2023, 19, 375-381.	0.8	0
91	A clinical case of myocardial infarction after coronary artery bypass grafting using the internal mammary artery. Bulletin of Siberian Medicine, 2023, 22, 159-164.	0.3	0
92	Factors determining the prognosis after elective myocardial revascularization in patients with coronary artery disease with multifocal atherosclerosis. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3689.	1.4	0
93	Feasibility of the assessment of longitudinal systolic deformation of the left ventricle in transesophageal atrial pacing stress echocardiography. Clinical case. Medical Alphabet, 2023, 1, 41-44.	0.2	0
94	24-hour blood pressure profile and systemic inflammation in patients with stable coronary artery disease with obstructive sleep apnea. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3705.	1.4	1
95	Reproducibility of instantaneous wave-free ratio and angiography coregistration in patients with coronary heart disease and diffuse and multilevel coronary artery lesion. Eurasian Heart Journal, 2023, , 32-40.	0.8	0
96	Retrospective Analysis of Lipid-Lowering and Antiplatelet Therapy Regimen by Clinical Decision Support Service Based on Real-World Data from Electronic Medical Records "Intellect 3 Study― Kardiologiya, 2023, 63, 46-56.	0.7	0

#	Article	IF	CITATIONS
97	Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity. Innovative Medicine of Kuban, 2023, , 6-14.	0.2	O
98	Angiocoregistration of instantaneous wave-free ratio using "virtual stenting―and results of real stenting in patients with coronary artery disease and diffuse coronary artery lesions. Kardiologicheskii Vestnik, 2023, 18, 92.	0.4	0
99	Associations of adipokines with coronary heart disease in young and middle-aged people., 2023, 19, 444-456.	0.1	0
100	Effectiveness of buffered acetylsalicylic acid compared to other drugs in diseases patients in clinical practice: results of the CARDINAL observational retrospective study. Russian Journal of Cardiology, 2023, 28, 5709.	1.4	0
101	Long-term outcomes of complete bilateral internal thoracic artery grafting and traditional coronary bypass surgery in patients with multivessel coronary artery disease. Russian Journal of Cardiology, 2023, 28, 5613.	1.4	0
102	The prevalence and factors associated with coronary heart disease in patients with gout. Nauchno-Prakticheskaya Revmatologiya, 2023, 61, 562-568.	1.0	0
103	Platelet phenotypes and practical aspects of platelet function testing in cardiology. Rational Pharmacotherapy in Cardiology, 2023, 19, 614-628.	0.8	0
104	Intraoperative atrial rhythm changes during atrial fibrillation catheter ablation in patients with arterial hypertension and coronary artery disease. Sibirskij žurnal KliniÄeskoj I A¨ksperimentalʹnoj Mediciny, 2024, 38, 167-175.	0.4	0
105	Factors associated with quality of life in patients with coronary artery disease before coronary artery bypass surgery. Sibirskij žurnal KliniÄeskoj I Ã"ksperimentalǹnoj Mediciny, 2024, 38, 213-221.	0.4	0
106	Pharmacogenetic predictors associated with reduced risk of secondary to enalapril cough. , 2024, 20, 109-116.		0
107	Risk Factors of Ischaemic Heart Disease in 419 385 Outpatients: a Long-term Comparative Study. Kardiologiya, 2024, 64, 63-66.	0.7	0
108	Influence of multimorbidity on the risk of events in men with chronic coronary artery disease after myocardial infarction and percutaneous coronary intervention. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3883.	1.4	0
109	Role of biomarkers of collagen metabolism and systemic inflammation in myocardial remodeling in patients with stable chronic coronary artery disease and obstructive sleep apnea. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3819.	1.4	0
110	Galectin-3 and structural and functional left ventricular characteristics in coronary artery disease in combination with chronic kidney disease. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784	3141r g BT /	Ov ø lock 10 T
111	Triple fixed-dose combination of amlodipine, indapamide and perindopril for hypertension in patients with stable coronary artery disease and abdominal obesity. Russian Journal of Cardiology, 2024, 29, 5753.	1.4	0
112	Combined use of beta-blockers and non-dihydropyridine calcium channel blockers: possible or contraindicated?. Russian Journal of Cardiology, 2024, 29, 5562.	1.4	0
113	The severity of chronic heart failure and the parameters of daily blood pressure profile in patients with coronary heart disease. Exploration of Medicine, 0, , 101-111.	1.5	0